Changes to UC Alternative Retirement Plan (ARP) and 403(b)
Plans will be effective on Oct. 1, 2020
The Investment Election window opened on Monday, Aug. 17, and will close on Sept. 19, 2020. Virtual town hall sessions are scheduled over the next few weeks to be held via WebEx. Participants are encouraged to review materials sent to their home as well as attend a WebEx town hall session. An on-demand, recorded version of the WebEx is also available.
As a reminder, the ARP is an offered alternative to the state retirement system (OPERS/STRS), and the university’s 403(b) is available for supplemental retirement plan savings. Changes to the ARP and the 403(b) include reducing the number of approved vendors in order to reduce plan and investment expenses as well as streamlining investment options so that enrollees can better create diversified investment portfolios and track fees.
For more information, refer to the 2020 ARP and 403(b) Retirement Plan Changes page on the Bearcats Landing intranet.
Questions?
Email the UC Benefits team at benefits@uc.edu.
Related Stories
UC faculty and staff among Rising Star leadership honorees
January 5, 2026
Two UC faculty and staff members are among this year's Rising Star leadership program sponsored by YWCA Greater Cincinnati. Kelli Beecher, assistant professor in the UC College of Nursing, and Brittany Bibb, assistant director of programs and operations in the UC Division of Student Affairs, are among the emerging leaders of 2026. They were featured in the publication Movers & Makers.
What's behind the mysterious rise of migraines?
January 5, 2026
Weather patterns such as extreme heat and storm conditions have been linked to migraine attacks, and research shows those environmental conditions are becoming more common. As National Geographic recently reported, one of the leading theories behind this mysterious rise is that climate change may be playing a role.
Top six 2025 nephrology drug approvals
January 5, 2026
“2025 has been a landmark year for kidney disease therapeutics, marked by a comprehensive slate of FDA approvals covering endothelin-receptor blockade, complement inhibition, GLP-1-based metabolic protection, and B-cell-directed therapy,” Prakash Gudsoorkar, MD, associate professor of clinical medicine at the University of Cincinnati College of Medicine and staff nephrologist at UC Health, recently told MedCentral.